+

WO2002011675A2 - Element nutritif organique destine au traitement de la calvitie - Google Patents

Element nutritif organique destine au traitement de la calvitie Download PDF

Info

Publication number
WO2002011675A2
WO2002011675A2 PCT/US2001/025257 US0125257W WO0211675A2 WO 2002011675 A2 WO2002011675 A2 WO 2002011675A2 US 0125257 W US0125257 W US 0125257W WO 0211675 A2 WO0211675 A2 WO 0211675A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
phytoestrogens
active component
riboflavin
biotin
Prior art date
Application number
PCT/US2001/025257
Other languages
English (en)
Other versions
WO2002011675A3 (fr
Inventor
M. D. Brian D. Zelickson
Original Assignee
Zelickson M D Brian D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zelickson M D Brian D filed Critical Zelickson M D Brian D
Priority to AU2001283322A priority Critical patent/AU2001283322A1/en
Publication of WO2002011675A2 publication Critical patent/WO2002011675A2/fr
Publication of WO2002011675A3 publication Critical patent/WO2002011675A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]

Definitions

  • compositions which are generally useful for the treatment of skin and hair. More specifically, the composition is useful for the treatment of androgenetica, also known as androgenetic alopecia or pattern hair loss, hi general, the composition of the present invention comprises one or more phytoestrogens, one or more natural herbal extracts, and optionally a pharmaceutically and/or dermatologically acceptable carrier. Other embodiments of the present invention comprise one or more phytoestrogens, one or more natural herbal extracts, one or more substances selected from the group consisting of vitamins, preferably b-complex vitamins, minerals and brewer's yeast and optionally a pharmaceutically and/or dermatologically acceptable carrier.
  • Alopecia has been a problem afflicting centuries and animals for thousands of years. In many individuals, alopecia causes embarrassment, psychological problems, including depression, and can affect one's self image and feelings of sexuality. Alopecia has been hypothesized to have various etiologies in males and females, many of which involve gonadal steroids. The loss of hair from the scalp is more common in men (e.g., male pattern baldness or androgenic alopecia) than in women (e.g., female pattern baldness). Cosmetic research has devoted millions of dollars and countless hours of research to solve this problem.
  • the pilar cycle can be broken down into three successive phases: the anagen phase the catagen phase and the telogen phase.
  • the anagen phase the hair undergoes a period of active growth associated with an intensive metabolic activity in the bulb.
  • the subsequent catagen phase is transitory and marked by a slowing-down of mitotic activity.
  • the final telogen phase corresponds to a period of rest for the follicle, with the hair being shed.
  • the hairs on the head are always in different stages of the cycle, so it is normal to loose scalp hair everyday.
  • hair growth depends on whether the hair growth selected for treatment is androgen-stimulated hair growth (e.g., beard hair and torso hair generally in humans) or hair growth that is not androgen-stimulated (e.g., scalp hair in humans).
  • Administration of an antiandrogen formulation topically in a dermatologically acceptable vehicle to an area of skin having androgen-stimulated hair growth or by administering the formulation by oral means, injection, suppository or other sublingual fonns in general causes a reduction in hair growth.
  • h male pattern hair loss the normal hair growth cycle is disrupted and more than the average number of hairs are shed per day without having the old hairs replaced by new ones.
  • Male pattern hair loss is determined by a combination of male hormones (androgens) and heredity. Men susceptible to male pattern baldness usually experience the onset sometime in their 20's and it becomes more common as they age. Androgenetic alopecia is the most common type of hair loss in men, with approximately 50% of men experiencing this hair loss to some degree by the age of 50.
  • adrogenetic alopecia In addition to adrogenetic alopecia, other factors may influence hair loss, many of which are temporary. Amongst these factors include stress of an illness or major surgery, medicines, such as those used in chemotherapy, blood tlnnners, antidepressants, excessive amounts of vitamin A and certain disease states like diabetes.
  • Minoxidil is applied topically to the scalp and has been shown to stimulate hair growth in individuals with androgenetic alopecia.
  • Another medication utilized for treatment of adrogenetic alopecia is Finisteride.
  • Finisteride a prescription antiandrogen medication, is an inhibitor of type II 5-alpha-reductase and has been shown to be effective in decreasing scalp DHT (dihydrotestosterone) by inhibiting conversion of testosterone to DHT.
  • DHT dihydrotestosterone
  • Oral administration of Finisteride slowed hair loss, increased hair growth and improved the appearance of hair.
  • Other anitandrogen medications which interfere with DHT binding at hormone receptor sites on hair follicle cells are Spironolactone, Cyproterone acetate, Estrogens and Cimetidine.
  • Another medicant believed to treat hair loss and stimulate hair growth is the use of herbal extracts or a combination of multiple herbal extracts. See for example, U.S. Patent No. 5,972,345.
  • Many herbal extracts which have been found to be useful in the treatment of benign prostatic hyperplasia, are further believed to have a natural affect on the skin and hair.
  • One such herbal extract is the extract of the berries of Saw Palmetto.
  • Saw Palmetto berries contain an oil with a variety of fatty acids and phytosterols.
  • the fat soluble extract of Saw Palmetto berries has been shown to inhibit the conversion of testosterone, which is thought to be responsible for the enlargement of the prostrate.
  • Saw Palmetto extract inhibits the binding of DHT to receptors, thus blocking DHT's action and promoting the breakdown of the potent compound.
  • Other herbal extracts such as African Pygeum and
  • Stinging Nettles Extract have been known as having potential in stimulating hair growth and more generally improving condition of the hair and skin.
  • composition of the present invention comprises one or more phytoestrogens, one or more natural herbal extracts, and optionally a pharmaceutically and/or dermatologically acceptable carrier.
  • Other embodiments of the present invention comprise one or more phytoestrogens, one or more natural herbal extracts, one or more substances selected from the group consisting of vitamins, preferably b-complex vitamins, minerals and brewer's yeast and optionally a pharmaceutically and/or dermatologically acceptable carrier.
  • embodiments of the composition of the present invention are generally useful for all types of skin and hair treatment. As previously mentioned, various embodiments of the composition are useful for the treatment of hair loss, and is especially useful for treatment of androgenetic alopecia. Furthermore, embodiments of the composition also may be utilized for the reduction or elimination of hair in areas of the human body which are androgen stimulated (i.e. the face or torso). Also, embodiments of the composition are effective in the prevention and treatment of acne.
  • One embodiment of the present invention comprises 80-99.5% herbal extract and .5-
  • Another preferred embodiment of the present invention comprises 85-
  • composition can be administered by various means including topical application, oral administration, injection, sublingual administration or any other systematic form of administration.
  • FIG 1 depicts the top view of the head of subject #1 following administration of the present invention for a period of one month.
  • FIG 2 depicts the top view of the head of subject #1 following administration of the present invention for a period of three months.
  • FIG 3 depicts the rear view of the head of subject #1 following administration of the present invention for a period of one month.
  • FIG 4 depicts the rear view of the head of subject #1 following administration of the present invention for a period of three months.
  • FIG 5 depicts a magnified view of a portion of the head of subject #1 following administration of the present invention for a period of one month.
  • FIG 6 depicts a magnified view of the head of subject #1 following administration of the present invention for a period of three months.
  • FIG 7 depicts the right side view of the head of subject #1 following administration of the present invention for a period of one month.
  • FIG 8 depicts the right side view of the head of subject #1 following administration of the present invention for a period of three months.
  • FIG 9 depicts the left side view of the head of subject #1 following administration of the present invention for a period of one month.
  • FIG 10 depicts the left side view of the head of subject #1 following administration of the present invention for a period of three months.
  • FIG 11 depicts the top view of the head of subject #2 following administration of the present invention for a period of one month.
  • FIG 12 depicts the top view of the head of subject #2 following administration of the present invention for a period of three months.
  • FIG 13 depicts the rear view of the head of subject #2 following administration of the present invention for a period of one month.
  • FIG 14 depicts the rear view of the head of subject #2 following administration of the present invention for a period of three months.
  • TABLE 1 depicts the terminal hair counts of subjects 1 and 2.
  • TABLE 2 depicts the percentage increase in terminal hair counts at three months for subjects 1 and 2.
  • the composition of the present invention comprises one or more phytoestrogens, one or more natural herbal extracts, and optionally a pharmaceutically and/or dermatologically acceptable carrier.
  • Other embodiments of the present invention comprise one or more phytoestrogens, one or more natural herbal extracts, one or more substances selected from the group consisting of vitamins, preferably b-complex vitamins, minerals and brewer's yeast and optionally a pharmaceutically and/or dermatologically acceptable carrier.
  • Each component of the composition is prepared according to the traditional procedures known in the art, then combined in a suitable composition for administration to the patient for treatment. The combining of the various components may be performed by the simple mixture of all the components in a single pot operation.
  • the phytoestrogens referred to in the previously described composition of the present invention include, but are not limited to the following: 1) Isoflavones, such as genistein, daidzein, biochanin A, and formononetin; 2) Lignans, or Resorcyclic Acid Lactones, such as matairesinol, secoisolariciresinol, enterolactone and enterodiol; 3) coumestans, such as coumestrol and 4) Equol, which is an estrogenic substance that results when intestinal bacteria break down either formononetin or daidzein. It has been found that the composition's inclusion of phytoestrogens enhances, accelerates and controls the systematic involvement of all the substances, in particular the herbal extracts, included in the composition.
  • red clover is utilized as a source of phytoestrogens.
  • Red clover can be used either by direct incorporation into the present composition or utilized to synthesize the phytoestrogens, which are subsequently incorporated into the composition.
  • the incorporation of red clover directly into the composition also provides vitamin A, vitamin C, B-complex, calcium, chromium, iron and magnesium to the composition.
  • the composition also includes one or more anti-androgen herbal extracts.
  • An herbal extract generally is the solution or preparation containing the active principles of the plant, herb, drug, juice or the like. Saw Palmetto, African Pygeum and Stinging Nettles Extract are examples of such herbal extracts. However, any herbal extract having anti-androgen characteristics may be used in the present invention.
  • Saw Palmetto as a component of the composition.
  • Saw Palmetto is a small palm tree with large leaves and largedeep red black berries.
  • Saw Palmetto berries contain an oil with a variety of fatty acids and phytosterols.
  • the fat soluble extract of Saw Palmetto berries has been shown to inhibit the conversion of testosterone, which is thought to be responsible for the enlargement of the prostrate.
  • Saw Palmetto extract inhibits the binding of DHT to receptors, thus blocking DHT's action and promoting the breakdown of the potent compound.
  • vitamins are vitamins and preferably b-complex vitamins.
  • these embodiments incorporate one or more of the following b-complex vitamins: Biotin, Thiamin,
  • present invention may also include the addition of other vitamins and minerals into the present composition.
  • Embodiments of the composition of the present invention may also include the addition of minerals and/or brewer's yeast.
  • Brewers yeast is an excellent source of several nutrients including thiamin (vitamin Bl), riboflavin (vitamin B2), nicotinic acid (Vitamin B3), pyridoxine (vitamin B6), pantothenic acid (Vitamin B5), biotin and folic acid, as well as some minerals and trace minerals, especially Chromium and Selenium. It also contains about 810 percent nucleic acid, which may have an immune enhancing effect. As previously mentioned one embodiment of the present invention comprises 80-
  • herbal extract 99.5% herbal extract and .5-20% Phytoestrogens as the active component of the composition.
  • Additional embodiments of the present invention comprise as an active component of the composition 50-95% herbal extract, 0-10% Biotin, .1-15% Thiamin, .1-15% Pyridoxine, 0- 10% Folic Acid, .1-15% Riboflavin, .5-20% Niacinamide, and .5-20% Phytoestrogens.
  • the percentage amounts reflect the "by mass" percentages and do not consider the amount of carrier, if a carrier is added to the composition.
  • a preferable embodiment of the active component of the composition comprises 85-95% herbal extract, .01-3% Biotin, .1-5% Thiamin, .1-5% Pyridoxine, .05-3% Folic Acid, .1-5% Riboflavin, .5-7% Niacinamide, and .5-8% Phytoestrogens. Again, the percentage amounts reflect the "by mass" percentages and do not consider the amount of carrier, if a carrier is added to the composition.
  • embodiments of the composition are generally useful for all types of skin and hair treatment.
  • the composition of the present invention is useful for the treatment of hair loss, and is especially useful for treatment of androgenetic alopecia.
  • embodiments of the composition also maybe utilized for the reduction or elimination of hair in areas of the human body which are androgen stimulated (e.g. the face or torso).
  • embodiments of the composition of the present invention are also useful in treatment of acne. These embodiments of the composition of the present invention are effective in the treatment and prevention of the previously mentioned conditions due to their inhibiting characteristic in reducing androgen from reaching androgen receptor sites.
  • the composition's active role in inhibiting androgen from reaching androgen receptor cites is linked to the treatment and prevention of hair loss from the scalp, the reduction of hair growth in androgen stimulated cites and the treatment and prevention of acne.
  • embodiments of the composition are suitable for providing an anti-androgenic effect when administered to a patient.
  • the administration of such embodiments of the composition maybe facilitated by topical application, oral administration, injection, suppository, sublingual forms or any other mode which is acceptable in administration of such compositions.
  • the composition is administered orally to a patient.
  • Oral dosage unit compositions include tablets, capsules, liquids and other conventional oral forms.
  • the composition may be alone or present in an amount of from about 10-100 percent by weight, with the inert carrier constituting the remainder of the tablet.
  • Typical pharmaceutically acceptable carriers include ingredients such as talcum, maize starch, polyvinyl pyrrolidone and lactose, together with a small amount of a tabletting agent such as magnesium stearate.
  • liquid oral dosage unit formulations may also be used in which the compositions are incorporated into vehicles conventionally used for lipid soluble compounds.
  • suppositories with the composition are also contemplated, to provide a rectal suppository administration of the drug, which form takes advantage of the usual suppository ingredients.
  • the high potency of the composition permits relatively low dosages both systemically, via oral or suppository routes, or through topical (transdermal) application.
  • the composition may be administered without the utilization of a pharmaceutically acceptable carrier.
  • the concentration of the active composition is from about 10-100 percent by weight of the composition, and generally from about 40 to 50 percent, is useful.
  • Topical application on an infrequent basis, through a sustained release delivery may indicate a relatively higher amount of the compositions, preferably in the range of from about 50-100 percent by weight.
  • a relatively lower concentration of the composition is indicated where a larger surface area is treated, such as the back, chest, etc., e.g., a concentration of from about .1-49 percent by weight.
  • a single oral dosage unit of the composition is administered as one oral dosage unit several times per day, in general up to about four times per day and preferably twice a day. For a normal adult male this compnses an amount of about 200 mg to 1000 mg per oral dosage unit and preferably from about 400 mg to 600 mg per oral dosage unit form.
  • the topical application of the composition may include a larger amount per topical dosage unit of the composition than the oral dosage unit. The general localization of the composition allows for a larger dosage to be administered.
  • the topical administration of the composition to a patient may also generally include a pharmaceutically and dermatologically acceptable carrier suitable for topical administration.
  • Pharmaceutically acceptable carriers include, but are not limited to, an alcohol, salve, suspension, emulsion, ointment, cream, powder or spray.
  • an alcohol such as ethanol and isopropanol are employed as pharmaceutically and dermatologically acceptable carriers.
  • the composition may be incorporated in liposomes or mixed with a penetration enhancer such as DMSO.
  • the composition is provided in a sustained release composition for transdermal application to the skin of a patient.
  • the sustained release carrier should be one which will maintain the composition at the skin and permit release to the skin for a period of preferably a minimum of about six to eight hours.
  • sustained release carrier is polyvinyl alcohol with a molecular weight of at least 8,000.
  • a polyvinyl alcohol having a molecular weight of about 20,000 is suitable for use with the composition.
  • any suitable sustained release carrier may be utilized with the composition.
  • a further embodiment provides a skin composition suitable for topical administration to a patient to be exposed to ultraviolet light which includes both the composition of the present invention and an ultraviolet screening agent such as para-aminobenzoic acid or cocoa butter.
  • Another embodiment of the invention is the incorporation of the composition into a shampoo which is advantageously provided for sufferers of skin problems and particularly, male pattern baldness.
  • the shampoo comprises conventional shampoo ingredients having incorporated therein the composition of the present invention.
  • Example 1 depict testing performed utilizing various embodiments of the present invention.
  • composition of the invention utilized in the observation was as follows:
  • Figures 2, 4, 6, 8 and 10 depict the top, rear, left side, right side and magnified views of the patient's head at three months which correspond to the respective areas shown in Figures 1, 3, 5, 7, and 9. It is noted that the patient reported a significant improvement in his acne since taking the composition. Furthermore, the patient did not experience any untoward side effects from taking the composition.
  • Example 2
  • composition of the invention utilized in the observation was as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition généralement utile dans le traitement de la peau et des cheveux. Plus particulièrement, cette composition est utile dans le traitement de l'alopécie androgénétique, également connue sous le nom de calvitie commune ou de pelade. De manière générale, le composition de l'invention contient un ou plusieurs phytoestrogènes, un ou plusieurs extraits naturels d'herbes, et éventuellement un excipient pharmaceutiquement et/ou dermatologiquement acceptable. D'autres modes de réalisation de l'invention comprennent un ou plusieurs phytoestrogènes, un ou plusieurs extraits naturels d'herbes, une ou plusieurs substances choisies dans le groupe constitué par des vitamines, et notamment des complexes de vitamine B, des minéraux et de la levure de bière, et éventuellement un excipient pharmaceutiquement et/ou dermatologiquement acceptable.
PCT/US2001/025257 2000-08-10 2001-08-10 Element nutritif organique destine au traitement de la calvitie WO2002011675A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001283322A AU2001283322A1 (en) 2000-08-10 2001-08-10 Organic nutrient for hair loss treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63709700A 2000-08-10 2000-08-10
US09/637,097 2000-08-10
US71117200A 2000-11-09 2000-11-09
US09/711,172 2000-11-09

Publications (2)

Publication Number Publication Date
WO2002011675A2 true WO2002011675A2 (fr) 2002-02-14
WO2002011675A3 WO2002011675A3 (fr) 2002-08-08

Family

ID=27092761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025257 WO2002011675A2 (fr) 2000-08-10 2001-08-10 Element nutritif organique destine au traitement de la calvitie

Country Status (2)

Country Link
AU (1) AU2001283322A1 (fr)
WO (1) WO2002011675A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087533A1 (fr) * 2001-04-26 2002-11-07 Beiersdorf Ag Utilisation d'extrait de trefle dans des preparations cosmetiques ou dermatologiques pour assurer la prophylaxie et le traitement d'eruptions cutanees degeneratives
DE102004039983A1 (de) * 2004-08-12 2006-03-02 Keller, Ben Pharmazeutische oder kosmetische Zusammensetzung
WO2006042370A1 (fr) * 2004-10-20 2006-04-27 Novogen Research Pty Ltd Méthodes et préparations pour cheveux et ongles
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
WO2008110268A1 (fr) * 2007-03-12 2008-09-18 Dsm Ip Assets B.V. Compositions cosmétiques
US8153684B2 (en) 2002-10-29 2012-04-10 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US20130142890A1 (en) * 2008-03-07 2013-06-06 S.W. Patentverwertungs Limited Composition and uses for influencing hair growth
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US20180168999A1 (en) * 2012-09-28 2018-06-21 Nutricos Technologies Use of a combination of taurine or a derivate thereof and a grape extract for improving the quality of the nails
DE102017008429A1 (de) 2017-09-07 2019-03-07 Dr. Theiss Naturwaren Gmbh Mittel zur Haarbehandlung
US20190151385A1 (en) * 2013-01-30 2019-05-23 The Beauty Cartel, LLC Hair Loss Treatment Compositions and Methods of Making and Using Same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US6017893A (en) * 1997-08-29 2000-01-25 Natures Sunshine Products, Inc. Use of isoflavones to prevent hair loss and preserve the integrity of existing hair
US5972345A (en) * 1999-05-03 1999-10-26 Chizick; Stephen Natural preparation for treatment of male pattern hair loss

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087533A1 (fr) * 2001-04-26 2002-11-07 Beiersdorf Ag Utilisation d'extrait de trefle dans des preparations cosmetiques ou dermatologiques pour assurer la prophylaxie et le traitement d'eruptions cutanees degeneratives
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US9408824B2 (en) 2002-07-24 2016-08-09 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US9173866B2 (en) 2002-07-24 2015-11-03 Children's Hospital Medical Center Compositions and products containing R-equol, and methods for their making
US7960432B2 (en) 2002-07-24 2011-06-14 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8048913B2 (en) 2002-07-24 2011-11-01 Australian Health & Nutrition Assoc. Ltd. Compositions and products containing S-equol, and methods for their making
US9018247B2 (en) 2002-07-24 2015-04-28 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US9889116B2 (en) 2002-10-29 2018-02-13 Bringham Young University Use of equol for treating androgen mediated diseases
US9408825B2 (en) 2002-10-29 2016-08-09 Brigham Young University Use of equol for treating androgen mediated diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US8450364B2 (en) 2002-10-29 2013-05-28 Brigham Young University Use of equol for treating androgen mediated diseases
US10111855B2 (en) 2002-10-29 2018-10-30 Brigham Young University Use of equol for treating androgen mediated diseases
US8153684B2 (en) 2002-10-29 2012-04-10 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US9089547B2 (en) 2002-10-29 2015-07-28 Brigham Young University Use of equol for treating androgen mediated diseases
DE102004039983A1 (de) * 2004-08-12 2006-03-02 Keller, Ben Pharmazeutische oder kosmetische Zusammensetzung
WO2006042370A1 (fr) * 2004-10-20 2006-04-27 Novogen Research Pty Ltd Méthodes et préparations pour cheveux et ongles
WO2008110268A1 (fr) * 2007-03-12 2008-09-18 Dsm Ip Assets B.V. Compositions cosmétiques
KR101500020B1 (ko) * 2007-03-12 2015-03-06 디에스엠 아이피 어셋츠 비.브이. 미용 조성물
US20130142890A1 (en) * 2008-03-07 2013-06-06 S.W. Patentverwertungs Limited Composition and uses for influencing hair growth
US11052059B2 (en) * 2008-03-07 2021-07-06 Lucolas - M.D. Ltd Composition and uses for influencing hair growth
US11974977B2 (en) 2008-03-07 2024-05-07 Lucolas—M.D. Ltd Composition and uses for influencing hair growth
US20180168999A1 (en) * 2012-09-28 2018-06-21 Nutricos Technologies Use of a combination of taurine or a derivate thereof and a grape extract for improving the quality of the nails
US11147302B2 (en) * 2012-09-28 2021-10-19 Nutricos Technologies Use of a combination of taurine or a derivate thereof and a grape extract for improving the quality of the nails
US20190151385A1 (en) * 2013-01-30 2019-05-23 The Beauty Cartel, LLC Hair Loss Treatment Compositions and Methods of Making and Using Same
DE102017008429A1 (de) 2017-09-07 2019-03-07 Dr. Theiss Naturwaren Gmbh Mittel zur Haarbehandlung
WO2019048326A1 (fr) 2017-09-07 2019-03-14 Dr. Theiss Naturwaren Gmbh Agent de traitement capillaire

Also Published As

Publication number Publication date
WO2002011675A3 (fr) 2002-08-08
AU2001283322A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
US6060070A (en) Isoflavonoids for treatment and prevention of aging skin and wrinkles
US6447762B1 (en) Hair lotion useful for treatment of hair loss and stimulating hair growth
US6420352B1 (en) Hair loss prevention
US20090123564A1 (en) Novel compositions for hair disorders and process of preparation thereof
US20040213859A1 (en) Organic nutrient for hair loss treatment
US5972345A (en) Natural preparation for treatment of male pattern hair loss
WO2002011675A2 (fr) Element nutritif organique destine au traitement de la calvitie
EP3991736A1 (fr) Composition pharmaceutique pour prévenir la chute des cheveux ou favoriser la pousse des cheveux, comprenant du ginsénoside rg4 ou un mélange (rgx 365) de ginsénosides rg2, rg4, rg6 et rh1 en tant que principe actif
JPH0517365A (ja) テストステロン ５α−レダクターゼ阻害剤
JPH0587491B2 (fr)
EP1890769A1 (fr) Tonifiant capillaire
KR19990018331A (ko) 모발 성장 촉진 조성물
WO2018229072A1 (fr) Composition pour prévenir la chute des cheveux et favoriser la croissance des cheveux
EP1620116B1 (fr) Utilisation du quinquina pour la preparation d'un medicament stimulant l'angiogenese
WO2000056269A2 (fr) Preparation naturelle pour le traitement de la perte de cheveux de type masculin
KR102538135B1 (ko) 천연 복합 추출물을 포함하는 탈모 예방 또는 발모 촉진용 조성물
KR100308491B1 (ko) 모발 성장 조성물
CN112915176B (zh) 一种防治脱发的草豆蔻组合物
US20060052405A1 (en) Hair loss prevention
KR20120046564A (ko) 천련자 추출물을 유효성분으로 함유하는 발모 및 두피 관리용 조성물
JPH0112725B2 (fr)
EP1313479A1 (fr) Prevention de la chute des cheveux
JPH05170623A (ja) 発毛促進剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载